Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals (Nasdaq: RYTM) appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17. Dr. Joshi brings more than 20 years of experience spanning discovery, pivotal trials, global regulatory processes and lifecycle management in rare diseases and other therapeutic areas.
He previously served as Chief Development Officer at Soleno Therapeutics, Chief Medical Officer at Neurona Therapeutics, and held senior clinical leadership roles at Atara Biotherapeutics, Allergan Medical, Synageva BioPharma, Genzyme and other organizations. Rhythm develops treatments for rare neuroendocrine diseases, led by IMCIVREE (setmelanotide), an MC4R agonist approved in the U.S., EU and UK for specific forms of acquired hypothalamic obesity and genetically defined obesity syndromes, and is advancing additional MC4R agonists and preclinical programs.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in adults and children aged ≥4 years with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO.
The decision is based on Phase 2 data and the global Phase 3 TRANSCEND trial in 120 patients, which met its primary endpoint with a -19.8% placebo-adjusted BMI reduction at 52 weeks. Setmelanotide-treated participants (n=81) had a mean BMI change of -16.5% versus +3.3% on placebo (n=39), with similar placebo-adjusted reductions in adults (-19.2%) and pediatric patients (-20.2%). IMCIVREE was generally well tolerated; common adverse events included nausea, vomiting, diarrhea, injection site reactions, skin hyperpigmentation and headache. Rhythm plans to work with the UK National Health Service to finalize coverage guidance.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will participate in fireside chats at three investor conferences: the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026 at 9:00 a.m. ET; the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026 at 3:00 p.m. ET; and the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 15, 2026 at 1:50 p.m. ET.
The webcasts and 30‑day replays will be accessible under “Events & Presentations” in the Investor Relations section of Rhythm’s website. Rhythm is a commercial-stage biopharmaceutical company whose lead product, IMCIVREE (setmelanotide), is approved in the U.S., EU and UK for certain rare, genetically driven obesities, with detailed indications and safety information provided.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported second quarter 2026 net product revenue of $71.3 million from global IMCIVREE sales, up from $48.5 million a year earlier and 19% sequentially, driven by the U.S. launch in acquired hypothalamic obesity (HO). U.S. revenue reached $51.0 million, up 38% quarter over quarter, while ex-U.S. revenue was $20.3 million, impacted by a $3.8 million retrospective charge in France. The company reported a Q2 net loss of $50.4 million and ended June 30, 2026 with $330.9 million in cash and investments, which, according to Rhythm, should fund operations for at least 24 months.
The U.S. HO launch generated more than 400 patient start forms from about 300 prescribers. Rhythm highlighted positive clinical and publication milestones, including Phase 1/2 RM-718 data showing a mean 11.6% BMI reduction in acquired HO after 16 weeks (n=7), publication of Phase 3 TRANSCEND HO results in the New England Journal of Medicine, and positive Phase 2 six‑month data for setmelanotide in Prader‑Willi syndrome. For 2026, Rhythm guides to $363–$397 million in non‑GAAP operating expenses (R&D $175–$195 million, SG&A $188–$202 million, excluding stock‑based compensation and certain in‑licensing costs).
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported preliminary data from its ongoing open-label Phase 2 trial of RM-718, a once-weekly MC4R agonist, in patients with acquired hypothalamic obesity. Eleven patients were enrolled; among seven patients evaluated at Week 16, mean BMI was reduced by 11.6% from baseline.
According to Rhythm, this BMI reduction is consistent with mean decreases previously observed for bivamelagon and setmelanotide at similar treatment durations. RM-718 was generally well tolerated; the most common adverse events were injection site reactions, nausea and vomiting, with two treatment discontinuations due to adverse events. Two mild hyperpigmentation cases were limited to injection sites, with no generalized hyperpigmentation. Eight patients remained on active treatment as of July 16, 2026. Rhythm will host a conference call and webcast today at 8:00 a.m. ET to discuss second quarter 2026 financial results and recent business activities.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update. Participants can register for the call online and are encouraged to join 10 minutes early.
An archived webcast will be posted under “Events and Presentations” in the Investor Relations section of Rhythm’s website about two hours after the call and remain available for 30 days. Rhythm is a commercial-stage biopharma company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the United States, European Union and United Kingdom for specific forms of acquired hypothalamic obesity and genetically defined syndromic or monogenic obesity, with detailed indications, limitations of use, and important safety information including warnings on hypersensitivity, depression, sexual arousal disturbances, skin hyperpigmentation, adrenal insufficiency, and sodium imbalance.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported that pivotal Phase 3 TRANSCEND trial results of setmelanotide in acquired hypothalamic obesity were published in The New England Journal of Medicine. The 52-week study showed substantial placebo-adjusted BMI reductions, improved hunger scores, and a safety profile without new signals, supporting recent FDA and EU regulatory milestones.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported multiple new data sets for its MC4R agonists setmelanotide and oral bivamelagon in acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS) and Prader-Willi syndrome (PWS) at ENDO 2026.
Highlights include long-term BMI reductions, weight category improvements, real-world weight loss and reduced obesity-related healthcare visits, alongside manageable adverse events.
Rhythm Pharmaceuticals (Nasdaq:RYTM) reported positive interim six‑month data from a Phase 2 trial of setmelanotide in patients with Prader‑Willi syndrome (PWS) presented at ENDO 2026.
Among 17 patients, results showed mean BMI reductions, fat mass loss with preserved lean mass, improved hyperphagia and anxiety measures, and safety consistent with the known profile, supporting advancement to Phase 3.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month Phase 2 results evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
The webcast and 30-day replay will be available in the Investor Relations section under Events and Presentations on the Rhythm Pharmaceuticals website.